Drug Details
General Information of the Drug (ID: DR9295) | ||||
---|---|---|---|---|
Name |
Tegafur
|
|||
Synonyms |
tegafur; Ftorafur; 17902-23-7; Futraful; Fluorofur; Sinoflurol; Citofur; Florafur; Fental; Neberk; Coparogin; Franroze; Furafluor; Furflucil; Furofutran; Nitobanil; Exonal; Fulfeel; Lifril; Sunfral; Lamar; Riol; Tefsiel C; FT-207; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; Phthorafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; MJF-12264; NSC-148958; N1-(2-tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydrofuran-2-yl)-5-fluorouracil; 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil; URACIL, 5-FLUORO-1-(TETRAHYDRO-2-FURYL)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-; FT 207; MFCD00012351; 5-Fluoro-1-(tetrahydro-3-furyl)uracil; 1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione; MLS000069497; 5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL; CHEBI:32188; 1-(2-TETRAHYDROFORMYL)-5-FLUOROURACIL; C8H9FN2O3; 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione; NCGC00159418-02; NCGC00159418-05; SMR000059106; Racemic Ftorafur; DSSTox_CID_1305; DSSTox_RID_76070; DSSTox_GSID_21305; Phthorafur [Czech]; Fluorafur; Tegafurum; Tegafurum [INN-Latin]; CAS-37076-68-9; CCRIS 2762; FT-207 (NSC 148958); FT207; EINECS 241-846-2; BRN 0525766; Franrose; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; Sunfural; Fulaid; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; N(sub 1)-(2-Tetrahydrofuryl)-5-fluorouracil; Tegafur [USAN:INN:BAN:JAN]; N(sub 1)-(2'-Furanidyl)-5-fluouracil [Czech]; Atillon (TN); Tegafur ,(S); N(sub 1)-(2'-Furanidyl)-5-fluouracil; TS-1 (Salt/Mix); Opera_ID_1726; UPCMLD-DP063; SCHEMBL4552; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; 5-24-06-00285 (Beilstein Handbook Reference); MLS000759414; MLS001076521; MLS001424119; CHEMBL20883; Tegafur (JP17/USAN/INN); F-5-FU; UPCMLD-DP063:001; GTPL10513; DTXSID001009966; HMS1665I05; HMS2051B15; HMS2090K04; HMS2232E05; HMS3371H21; HMS3393B15; HMS3654P13; HMS3715D14; N1-(2'-Furanidyl)-5-fluouracil; 2,4(1H,3H)Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione; BCP22714; 5-fluoro-1-(tetrahydrofuran-2-yl); N1-(2'-Furanidyl)-5-fluorouracil; Tox21_111649; Tox21_301812; BBL027795; CCG-50110; STK528044; Tegafur, >=98% (HPLC), powder; 5-Fluoro-1-(2-tetrahydrofuryl)uracil; AKOS000121279; Tox21_111649_1; AC-2112; CCG-100959; CS-1128; DB09256; MCULE-1366455644; NC00209; 1-(tetrahydro-2-furyl)-5-fluorouracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.; 5-fluoro-1-(2-tetrahydrofuranyl)uracil; N1 -(2-tetrahydrofuryl)-5-fluorouracil; NCGC00159418-04; NCGC00255222-01; 79107-97-4; 82294-77-7; AK468738; AS-13528; HY-17400; I580; FT-0653732; FT-0654170; FT-0674829; FT-0693965; C12673; D01244; J10344; W-5041; AB00572620-15; 902T237; Q413370; SR-01000639511; Q-201784; SR-01000639511-1; SR-01000639511-4; 5-fluoro-1-tetrahydro-furan-2-yl-1H-pyrimidine-2,4-dione; 5-Fluoro-1-tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione; 2, 4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C8H9FN2O3
|
|||
PubChem CID | ||||
Canonical SMILES |
C1CC(OC1)N2C=C(C(=O)NC2=O)F
|
|||
InChI |
1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
|
|||
InChIKey |
WFWLQNSHRPWKFK-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 17902-23-7
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Cystine | Gallus gallus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity. |
